AdAlta (1AD) Stock Price, News & Analysis

Company Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 135,957 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

1AD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of AdAlta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AdAlta investors own include Advanced Micro Devices (AMD), Alibaba Group (BABA), Brookline Capital Acquisition (BCAC), Banxa (BNXAF), Crane (CR), Ford Motor (F) and GS Acquisition Holdings Corp II (GSAH).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:1AD
• CIK: N/A
• Web: www.adalta.com.au
• Phone: 61 3 9479 5159
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -273.13%
• Return on Assets: -50.02%

Debt

• Debt-to-Equity Ratio: 138.65
• Current Ratio: 2.38
• Quick Ratio: 2.84

Sales & Book Value

• Annual Sales: $1.74 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.94
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 606,210,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.63